JUNS (Jupiter Neurosciences) Short Percentage of Float


JUNS Jupiter Neurosciences Inc JUNS
4 GF Score
Price $0.28
! 6 Warning Signs
View Full Analysis

What is Jupiter Neurosciences Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

JUNS vs ZEOX, LEXX, GDTC: Short Percentage of Float Comparison

For the Biotechnology subindustry, Jupiter Neurosciences's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Jupiter Neurosciences Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jupiter Neurosciences's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Jupiter Neurosciences's Short Percentage of Float falls into.


JUNS
4GF Score
Jupiter Neurosciences Inc JUNS
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jupiter Neurosciences Business Description

Address 1001 North US Highway 1, Suite 504, Jupiter, FL, USA, 33477
Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.
4GF Score

Get the complete analysis for JUNS

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.28
Price